Literature DB >> 20113900

Venous thromboembolism in children.

Neil A Goldenberg1, Timothy J Bernard.   

Abstract

With improved pediatric survival from serious underlying illnesses, greater use of invasive vascular procedures and devices, and a growing awareness that vascular events occur among the young, venous thromboembolism (VTE) increasingly is recognized as a critical pediatric concern. This review provides background on etiology and epidemiology in this disorder, followed by an indepth discussion of approaches to the clinical characterization, diagnostic evaluation, and management of pediatric VTE. Prognostic indicators and long-term outcomes are considered, with emphasis on available evidence underlying current knowledge and key questions for further investigation. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113900     DOI: 10.1016/j.hoc.2009.11.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  10 in total

Review 1.  How We Manage Pediatric Deep Venous Thrombosis.

Authors:  Marisol Betensky; Mark A Bittles; Paul Colombani; Neil A Goldenberg
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

2.  Endovascular thrombolysis to salvage central venous access in children with catheter-associated upper extremity deep vein thrombosis: technique and initial results.

Authors:  Matthew P Lungren; Thomas J Ward; Manish N Patel; John M Racadio; Kamlesh Kukreja
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

3.  Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation.

Authors:  Brian R Branchford; Peter Mourani; Lalit Bajaj; Marilyn Manco-Johnson; Michael Wang; Neil A Goldenberg
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

4.  Deep vein thrombosis: thrombolysis in the pediatric population.

Authors:  Lindsey A Greene; Neil A Goldenberg
Journal:  Semin Intervent Radiol       Date:  2012-03       Impact factor: 1.513

5.  Perioperative Transfusions and Venous Thromboembolism.

Authors:  Ruchika Goel; Cassandra D Josephson; Eshan U Patel; Molly R Petersen; Sarah Makhani; Steven M Frank; Paul M Ness; Evan M Bloch; Eric A Gehrie; Parvez M Lokhandwala; Marianne M Nellis; Oliver Karam; Beth H Shaz; Ravi M Patel; Aaron A R Tobian
Journal:  Pediatrics       Date:  2020-03-20       Impact factor: 7.124

6.  Characteristics of abdominal vein thrombosis in children and adults.

Authors:  Daniel Landi; Michele G Beckman; Nirmish R Shah; Paula Bockenstedt; Althea M Grant; John A Heit; Nigel S Key; Roshni Kulkarni; Marilyn Manco-Johnson; Stephan Moll; Claire S Philipp; Judith C Andersen; Thomas L Ortel
Journal:  Thromb Haemost       Date:  2013-02-14       Impact factor: 5.249

7.  Treatment and outcome of childhood cerebral sinovenous thrombosis.

Authors:  Ryan J Felling; Sahar M A Hassanein; Jennifer Armstrong; Luis Aversa; Lori Billinghurst; Neil A Goldenberg; Jo Ellen Lee; Emily C Maxwell; Michael J Noetzel; Warren Lo
Journal:  Neurol Clin Pract       Date:  2020-06

8.  Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.

Authors:  Bharat Damle; Frank Jen; Nancy Sherman; Darshana Jani; Kevin Sweeney
Journal:  J Clin Pharmacol       Date:  2020-08-21       Impact factor: 3.126

9.  The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry.

Authors:  Martine A Aardoom; Renz C W Klomberg; Polychronis Kemos; Frank M Ruemmele; C H Heleen van Ommen; Lissy de Ridder; Nicholas M Croft
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

10.  Is Swine-origin Influenza a Predisposing Factor for Deep Vein Thrombosis?

Authors:  Müge Gökçe; Sule Unal; Selin Aytaç; Ateş Kara; Mehmet Ceyhan; Murat Tuncer; Fatma Gümrük
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.